



Chairmen: Ian Stratford  
Paul Workman  
Norman Coleman

---



*Ninth International Conference on  
Chemical Modifiers of Cancer Treatment*

August 22–26, 1995, Christ Church, Oxford, UK

In honour of: Gerald E. Adams  
Norman M. Bleehan  
Stanley Dische

## ACKNOWLEDGEMENTS

*Sponsors*

Cancer Research Campaign  
Sanofi Winthrop

*Benefactors*

International Association for Radiation Research  
Associates of the Joint Center for Cancer Therapy (Boston)  
British Oncological Association  
US Bioscience  
Varian Associates  
United Kingdom Co-ordinating Committee for Cancer  
Research  
Eppendorf  
Warner-Lambert/Parke-Davis

*Contributors*

Zeneca Pharmaceuticals  
Lilly Industries Limited  
IMPAC Medical Systems  
Oxford Optronix

With additional support from the Medical Research Council.



The *British Journal of Cancer* is published twice monthly on behalf of the *Cancer Research Campaign* by Stockton Press, a division of Macmillan Press Ltd.

**Scope** The *British Journal of Cancer* will consider papers which contain new information, constitute a distinct contribution to knowledge, and are relevant to the clinical, epidemiological, pathological or molecular aspects of oncology.

This journal is covered by *Excerpta Medica*, *Current Advances in Genetics and Molecular Biology*, *Current Contents*, *Medline*, *Index Medicus*, *Index to Scientific Reviews* and *Science Citation Index*.

**Editorial** Manuscripts (plus three copies) and all editorial correspondence should be sent to: Professor GE Adams, Editorial Office, *British Journal of Cancer*, MRC Radiobiology Unit, Chilton, Didcot, Oxfordshire OX11 0RD, UK.  
Tel: +44 (0) 1235 832141. Fax: +44 (0) 1235 832142.

**Advertisements** Enquiries concerning advertisements should be addressed to: Michael Rowley, Hasler House, High Street, Great Dunmow, Essex, CM6 1AP, UK.  
Tel: +44 (0) 1371 874613. Fax: +44 (0) 1371 872273.

**Publisher** All business correspondence and reprint requests should be addressed to *British Journal of Cancer*, Stockton Press, Houndmills, Basingstoke, Hampshire RG21 6XS, UK. Tel: +44 (0) 1256 29242. Fax: +44 (0) 1256 810526.  
Publisher: Jayne Marks  
Production Controller: Debbie Cole  
Supplement Editor: Alice Ellingham  
Supplement Production Controller: Simone Larché

**Subscriptions - EU/Rest of World** Subscription price per annum (two volumes, 24 issues), EU £430, rest of the world £470 (surface), £560 (airmail), or equivalent in any other currency. Orders must be accompanied by remittance. Cheques should be made payable to *Macmillan Magazines* and sent to: The Subscription Department, Macmillan Press Ltd, Houndmills, Basingstoke, Hampshire, RG21 6XS, UK. Where appropriate, subscribers may make payments into UK Post Office Giro Account No. 519 2455. Full details must accompany the payment. Subscribers from EU territories should add sales tax at the local rate.

**Subscriptions - USA** USA subscribers call toll free 1-800-221 2123 or send check/money order/credit card details to: Stockton Press, 345 Park Avenue South, 10th Floor, New York, NY 10010-1707. Tel: +1 212 689 9200. Fax: +1 212 689 9711. USA annual subscription rates (institutional/corporate): \$745 (surface), \$890 (airmail). Prices are set in UK Sterling. Dollar prices are converted to UK Sterling at the current exchange rate. Accord-

ingly, your credit card charge may vary slightly from the dollar rate shown. To obtain the exact dollar rate shown above, please remit by check. All prices are subject to change without notice.

The *British Journal of Cancer* (ISSN 0007-0920) is published twice a month by Macmillan Press Ltd. c/o Mercury Airfreight International Ltd, 2323 Randolph Avenue, Avenel, NJ 07001, USA. Subscription price for institutions is \$890 per annum. 2nd class postage is paid at Rahway NJ. Postmaster: send address corrections to Macmillan Press Ltd, c/o Mercury Airfreight International Ltd, 2323 Randolph Avenue, Avenel, NJ 07001, USA

**Reprints** of any article in this journal are available from Stockton Press, Houndmills, Basingstoke, Hampshire RG21 6XS, UK. Tel: +44 (0) 1256 29242. Fax: +44 (0) 1256 810526.

**Copyright** © 1996 Cancer Research Campaign  
ISSN 0007-0920

All rights of reproduction are reserved in respect of all papers, articles, illustrations, etc, published in this journal in all countries of the world.

All material published in this journal is protected by copyright, which covers exclusive rights to reproduce and distribute the material. No material published in this journal may be reproduced or stored on microfilm or in electronic, optical or magnetic form without the written authorisation of the Publisher.

Authorisation to photocopy items for internal or personal use of specific clients, is granted by Stockton Press, for libraries and other users registered with the Copyright Clearance Centre (CCC) Transaction Reporting Service, provided that the base fee of \$12.00 per copy is paid directly to CCC, 21 Congress St, Salem, MA 01970, USA 0007-0920/96 \$12.00 + \$0.00

Apart from any fair dealing for the purposes of research or private study, or criticism or review, as permitted under the Copyright, Designs and Patent Act 1988, this publication may be reproduced, stored or transmitted, in any form or by any means, only with the prior permission in writing of the publishers, or in the case of reprographic reproduction, in accordance with the terms of licenses issued by the Copyright Licensing Agency.

Whilst every effort is made by the publishers and editorial board to see that no inaccurate or misleading data, opinion or statement appears in this Journal, they wish to make it clear that the data and opinions appearing in the articles and advertisements herein are the responsibility of the contributor or advertiser concerned. Accordingly, the publishers and the Cancer Research Campaign, the editorial committee and their respective employees, officers and agents accept no liability whatsoever for the consequences of any such inaccurate or misleading data, opinion or statement. Whilst every effort is made to ensure that drug doses and other quantities are presented accurately, readers are advised that new methods and techniques involving drug usage, and described within this Journal, should only be followed in conjunction with the drug manufacturer's own published literature.

## FACULTY

<b>Chairman</b>	Ian J Stratford (UK)	
<b>Co-Chairmen</b>	Paul Workman (UK) Norman Coleman (USA)	
<b>Organising Committee</b>	Alberto Breccia (Italy) Martin Brown (USA) Luciano Busutti (Italy) Don Chapman (USA) Tom Connors (UK) Eric Hall (USA) Ralph E Durand (Canada) Tsutomu Kagiya (Japan) Stan Kaye (UK) Timothy Kinsella (USA)	Edmund Malaise (France) James Mitchell (USA) Jens Overgaard (Denmark) Theodore Phillips (USA) Garth Powis (USA) Mike Rauth (Canada) Dietmar Siemann (USA) Yoshimasa Tanaka (Japan) Robert Sutherland (USA) Todd Wasserman (USA) Gordon Whitmore (Canada)
<b>Local Organising Committee</b>	Dai Chaplin Adrian Harris Adrian Jones	George Radda Peter Wardman
<b>Honoured Guests</b>	Gerald Adams Norman Bleehen	Stanley Dische
<b>Keynote Speakers</b>	Gabi Dachs (UK) Bill Denny (New Zealand) John Griffiths (UK) Ian Hickson (UK) Lynn Hlatky (USA)	Paul Okunieff (USA) David Ross (USA) Michelle Saunders (UK) Ken Tew (USA)
<b>Young Investigator Awards</b>	Christine Brezden (Canada) David Cowan (New Zealand) Sara Fitzsimmons (UK) Ruth Langley (UK) Carrie Peters (Canada) Bronwyn Simm (USA) Xiaoping Sun (PR China) Ingunn Tufto (Norway) Carolien Versantvoort (UK) Bradley Wouters (Canada)	

# British Journal of Cancer

## Editor-in-Chief

GE Adams

*Didcot, Oxon*

## Subject Editors

### Clinical Oncology

SB Kaye

*Glasgow*

### Epidemiology

LJ Kinlen

*Oxford*

### Pathology

D Wynford-Thomas

*Cardiff*

### Cell and Molecular Biology

EG Wright

*Didcot, Oxon*

### Experimental Therapeutics

GE Adams

*Didcot, Oxon*

## EDITORIAL BOARD

### Chairman

DG Harnden

*Manchester*

K Alitalo - *Helsinki*  
DM Barnes - *London*  
M Baum - *London*  
DT Bishop - *Leeds*  
A-L Børresen - *Oslo*  
P Boyle - *Milan*  
HJ Broxterman - *Amsterdam*  
J Cassidy - *Aberdeen*  
TA Connors - *Sutton*  
TG Cooke - *Glasgow*  
D Crowther - *Manchester*  
J Cuzick - *London*  
M D'Incalci - *Milan*  
J-P Droz - *Lyon*  
MJ Embleton - *Manchester*  
B Franc - *Boulogne*  
P Gallimore - *Birmingham*  
PA Hall - *Dundee*

SR Hamilton - *Baltimore*  
KR Harrap - *Sutton*  
AL Harris - *Oxford*  
IR Hart - *London*  
J Hickman - *Manchester*  
A Horwich - *Sutton*  
DK Hossfeld - *Hamburg*  
N Hynes - *Basel*  
LJ Kinlen - *Oxford*  
NR Lemoine - *London*  
RCF Leonard - *Edinburgh*  
LA Liotta - *Bethesda*  
TA Lister - *London*  
D Machin - *Cambridge*  
JG McVie - *London*  
D Metcalf - *Melbourne*  
WR Miller - *Edinburgh*  
JV Moore - *Manchester*

M Piccart - *Brussels*  
M Pignatelli - *London*  
B Ponder - *Cambridge*  
J Pritchard - *London*  
JE Roulston - *Edinburgh*  
N Saijo - *Tokyo*  
PJ Selby - *Leeds*  
RL Souhami - *London*  
WP Steward - *Ontario*  
IF Tannock - *Toronto*  
JM Trent - *Ann Arbor*  
PR Twentyman - *Cambridge*  
V Van Heyningen - *Edinburgh*  
J Verweij - *Rotterdam*  
NJ Wald - *London*  
P Workman - *Macclesfield*  
JA Wyke - *Glasgow*

### Editorial Assistants

Catherine O'Hara - *Didcot, Oxon*  
Jackie McMinn - *Didcot, Oxon*

Sandra Hooper - *Cardiff*  
Jenny Bailey - *Didcot, Oxon*

Phyllis Scott - *Glasgow*  
Janette Wallis - *Oxford*

## Message from the Chairmen

These proceedings provide a flavour of the 9th International Conference on Chemical Modifiers of Cancer Treatment. This meeting consisted of 196 oral contributions, including keynote talks, as well as 4 minute/4 slide presentations. This format has been a feature of the more recent Chemical Modifier meetings and the talks were accompanied by extended abstracts given to participants at the time of the meeting.

Presentations were representative of virtually all areas covered in previous Chemical Modifier meetings and indicated that the field is continuing to evolve. This is coming about, in part, by the application of new techniques derived from molecular biology. Thus, redox changes that occur in tumours (which previously have been considered major problems) are now recognised to cause substantial changes in cellular biochemistry. This better understanding of cell and tumour biology will provide new avenues for therapeutic exploitation.

The return of the Chemical Modifiers meeting to the UK coincides with the 'retirement' of three pioneers in the field, namely Professors Ged Adams, Norman Bleehen and Stanley Dische. It was they who organised the first Chemical Modifiers meeting in 1977, the proceedings of which were published in the *British Journal of Cancer* (38, suppl. III). Since then, these 'pioneers' have worked tirelessly in developing many of the concepts derived from, and included in, later meetings. Their work has set the highest standard and it is hoped that these proceedings provide a small tribute to these leaders, whose work one equates with scientific excellence.

Finally, the conference and the publication of these proceedings has been made possible by the tireless efforts of the secretarial team – Vikki Fielden and Jane McCourt at the MRC Harwell and Simone Larché at Stockton Press. Special thanks go to the Medical Research Council and, for generous major sponsorship, to the Cancer Research Campaign and the pharmaceutical company Sanofi Winthrop.

Science and the field of Chemical Modifiers moves on. The next meeting is in Florida, USA, in January 1998, chaired by Professor Dietmar Siemann. Enjoy these Proceedings and look forward to the next.

**Ian Stratford, Paul Workman and Norman Coleman  
(Co-Chairmen)**



## Author index to Supplement 27

- Abe M S61  
Aboagye EO S226  
Abraham SK S102  
Adams GE S177, S232  
Adomat H S200  
Anderson RF S48  
Arnold S S164, S168, S260  
Atkovar G S282
- Ballinger JR S264  
Banáth JP S191  
Barzilay G S145  
Batchelder RM S52  
Beall HD S1  
Begleiter A S9  
Belej T S23  
Bell KM S161  
Bernhard E S140  
Biaglow J S140  
Biaglow JE S222  
Bleehen NM S236  
Bloomer WD S267  
Bonner JA S109  
Boyles DJS S78  
Braun RD S241, S247  
Braunhut SJ S157  
Brezden CB S19  
Briggs LA S15  
Brizel DM S241  
Broadhurst S S99  
Budd R S99  
Bump EA S117, S157
- Cervený C S78  
Chadwick JA S75  
Chaplin DJ S75, S86, S122, S133, S161, S164, S168, S260  
Chapman JD S204, S209  
Chin L S78  
Chou S-C S213  
Christodoulou D S181  
Ciaccio PJ S93  
Coia LR S204  
Coleman CN S117, S151, S297  
Collingridge D S168  
Cook JA S181  
Cornwell MM S78  
Cowan DSM S28, S264  
Curphey TJ S9
- D'Abrew S S99  
Dachs GU S126  
de Bie J S185  
DeGraff W S181  
Delfs JR S117  
Dennis MF S70, S172
- Denny WA S32, S43, S48, S52  
Dewhirst MW S241, S247  
Ding I S105  
Dische S S271  
Dobrowsky E S279  
Dobrowsky W S279  
Dunphy EP S185
- Engelhardt EL S204  
Everett SA S70, S172
- Farrell N S200  
Fenning MC S204  
Fingar VH S89  
Fisher J S181  
Flood PM S213  
Fowler JF S294  
Friery OP S39  
Fryer CJH S122
- Gamson J S181  
Geula C S117  
Goodman GB S122  
Grasl M S279  
Griffin RJ S217  
Griffiths JR S226  
Gustafson DL S1
- Hahnfeldt P S151  
Halinska A S23  
Hall EJ S57  
Hay MP S32, S52  
Hei TK S57  
Hejmadi MV S39  
Hicks KO S28  
Hickson ID S145  
Hill SA S86, S168, S260  
Hiraoka M S61, S114  
Hirohashi M S114  
Hirst DG S39  
Hlatky L S151  
Höckel M S185  
Hofstrand P S78  
Honest DJ S236  
Hong K S247  
Horsman MR S168, S232  
Hoskin PJ S260  
Huang K S105  
Hur W-J S217  
Hurwitz SJ S117
- Inomata T S122  
Iwata K S217
- Jackson SM S191  
Ji M S267  
Johnsen NM S136
- Kautzky M S279  
Kelly DP S99  
Kesavan PC S102  
Kim S S222  
Kimura H S247  
King P S200  
Kinsella TJ S294  
Kitamoto Y S236  
Koch C S200  
Köhler W S279  
Krishna MC S181  
Kuehl BL S19
- Lai L S157  
Lam GYK S122  
Lamppu DM S82  
Le Riche J S191  
Leahy M S260  
Lee HH S43  
Leith MK S9  
Li AE S43  
Lindberg RD S89  
Liu SX S57  
Lord E S200  
Lyng H S136, S252
- McCoy CL S226  
McEwan AG S209  
McIntyre DJO S226  
McIntyre IA S39  
McKenna WG S140  
McKeown SR S39  
Makepeace CM S217  
Manevich Y S222  
Mannan RH S209  
Martin RF S99  
Matthews J S200  
Maurer BJ S78  
Maxwell RJ S232  
Medeiros D S157  
Melo T S264  
Menton-Brennan L S117  
Mercer JR S209  
Millesi W S279  
Mitchell JB S181  
Miyachi S S114  
Morin C S209  
Murata R S61, S114  
Muschel R S140
- Naudé J S279  
Naylor MA S70  
Nishioka A S122  
Nordmark M S232
- Obeid A S260  
O'Brien PJ S23, S287  
Ogawa Y S122
- Okkan S S282  
Okunieff P S105, S185  
Olive PL S191  
Ong ET S241  
Overgaard J S168, S232  
Oya N S61, S114
- Palayoor ST S117  
Palcic B S122, S200  
Papadopoulou MV S267  
Papahadjopoulos D S247  
Park L S264  
Parkins CS S75  
Parliament MB S209  
Patel KB S70, S172  
Patterson LH S39, S43  
Pavelka R S279  
Pavlovic M S222  
Pettit GR S86  
Pigott KH S260  
Poulin N S200  
Powell MEB S260  
Prise VE S161  
Pritsos CA S15  
Priyadarsini KI S70  
Pullen SM S43
- Radacic M S168  
Raleigh JA S213  
Rampling MR S236  
Rasey JS S78  
Rauth AM S19, S264  
Rehmus SW S241  
Rehmus SWE S247  
Reichel M S279  
Renzing J S19  
Reum M S99  
Robinson SP S226  
Rofstad EK S136, S252  
Rosner GL S241  
Ross D S1, S19  
Rothwell DG S145
- Sahinler I S282  
Sampson LE S133  
Sangulin J S200  
Sansom JM S177  
Saroff DM S117  
Sasai K S61, S114  
Saunders M S271  
Saunders MI S260  
Sawyer TE S109  
Schneider RF S204  
Secomb TW S241, S247  
Sephton R S99  
Shakil A S217  
Shan S S241  
Shibamoto Y S61, S114



- Shibata T S61  
Siegel D S1, S19  
Siemann DW S65  
Sigdestad CP S89  
Singh SP S102  
Skov K S200  
Smith KA S172  
Song CW S217  
Sood C S287  
Stevenson MA S117  
Stobbe CC S204  
Stratford IJ S70, S126, S177,  
S232  
Stratford MRL S70, S172
- Szabo C S177
- Takagi T S61, S114  
Takahashi M S61  
Terris DJ S185  
Tew KD S93  
Thiemermann C S177  
Thompson KM S43  
Tishler RB S82  
Tozer GM S161  
Tracy M S70  
Traver RD S1, S19  
Trotter T S191  
Tsiou C S151
- Tufto I S252  
Turkan S S282  
Tuttle S S140
- Urtasun RC S209  
Uzel R S282
- Vane JR S177  
Vojnovic B S256
- Walker LJ S145  
Ward G S260  
Wardman P S70, S172, S256  
Ware DC S48
- Watts ME S164  
Wheeler KT S196  
Wiebe LI S209  
Wieman TJ S89  
Wilson GD S279  
Wilson WR S28, S32, S43,  
S48, S52  
Wink DA S181  
Wood PJ S168, S177, S232  
Wróblewski K S222  
Wu T S105
- Young WK S256  
Zhang H S196



## Subject index to Supplement 27

- Acridine S28, S267  
Actin filaments S157  
ADEPT S32  
Amiloride S75  
Apoptosis S145, S172  
AQ4N S39, S43  
Artificial antigens S213  
ATP S15
- Bioreductive antitumour agents S9  
Bioreductive drugs S15, S43, S48, S57, S65, S209  
Bloodflow S86  
BMS181321 S264  
BOF-A2 S114  
Bone marrow S105  
Bone marrow toxicity S65  
BSO S93  
BUdR S294
- Camptothecin S109  
Carbogen S241  
Carbon spin resonance S226  
Cardiotoxicity S15  
Cell contact S78  
Cell cycle distribution S109  
Cervix S282  
CHART S271, S279  
Chlorambucil S75  
Chloroethanol S287  
Clastogenic mechanism S52  
CNDP S114  
Combination chemotherapy S65  
Combretastatin S86  
Comet assay S191  
Cytokines S105, S133  
Cytokinesis-block micro-nucleus assay S61  
Cytotoxicity S23, S172  
    clastogenic mechanism of S52  
    hypoxia selective S48  
Cytotoxins, radiation activated S32
- 3-D cell growth S78  
DACA S43  
Dihydrodiol dehydrogenase S93  
1,2-Dithiole-3-thione S9  
DMXAA S43  
DNA damage S145  
DNA repair S145  
DNA strand breaks S196  
DNA targeting S200  
DNA–protein cross links S196
- Dolastatin S86  
Drug resistance S264  
DT-diaphorase S1, S9, S19, S23, S93
- E09 S1, S9  
Endothelial cells S151  
    human umbilical vein S164  
Endothelin A receptors S161  
Endothelin B receptors S161  
Endothelin-1 S161  
Energy metabolism S232  
Eppendorf oxygen electrode S168  
EPR spectroscopy S172  
Erythrocyte flux S260  
Erythropoietin S126  
Ethacrynic acid S93
- FAA S86
- Garlic S102  
GDEPT S32  
Gene expression S151  
Gene therapy S126  
9L glioma S222  
Glucose S222  
 $\alpha$ -Glutamylcysteine synthetase S93  
Glutathione depletion S109  
Glutathione S-transferase S102
- HAP1 S145  
Heterocyclic N-oxide S57  
Hoechst 33342 S99  
HT29 tumour S260  
Human leucocyte filterability S236  
Hydrogen abstraction S70  
Hydroperoxide S140  
Hydroxyguanidine S172  
Hyperoxia S241  
Hyperthermia S168  
Hypoxia S28, S32, S43, S61, S117, S126, S136, S151, S164, S181, S185, S196, S200, S209, S217, S232, S256, S260, S267, S279  
    acute S236  
    human tumour S191  
Hypoxia inducible factor 1 S126  
Hypoxia markers S213  
Hypoxic cells S264  
Hypoxic toxicity S57
- Ifosfamide S287
- Image cytometry S200  
Imaging S209  
Interstitial fluid pressure S252  
Intracellular pH S75  
Iodoazomycin arabinoside S204, S209  
 $\beta$ -D-Iodoazomycin xylopyranoside S204  
IUdR S294
- Ketamine S222  
KU-2285 S61
- Labelling indices S294  
Lactate S226  
Laser Doppler flowmetry S168  
Lymphoblasts S23
- Magnetic resonance spectroscopy S226  
MDA-MB-231 cells S164  
Melanomas S136  
Melanoma xenografts S252  
Metastases S122  
Microcirculation S157  
Micronucleus formation S52  
Micronucleus test S102  
Minor groove binding S99  
Misonidazole S28  
Mitochondrial DNA S15  
Mitomycin C S1, S9, S19, S279  
Monolayers S78  
*myc* S140  
Myoglobin S226
- Neocarzinostatin S52  
Neurotoxicity S117  
Nicotinamide S236, S271  
Nigericin S75  
Nitric oxide S172, S177, S181  
Nitro-L-arginine S168  
Nitroimidazole S200, S209, S213, S267  
Nitroimidazole probes S226  
Nitroxide S157  
NLA-1 S267  
NLP-1 S267  
NQO1 S1
- Oncogenicity S57  
One-electron reduction S48, S57  
Ornidazole S282  
N-Oxides S70  
Oxygen electrodes S217  
Oxygen enhancement ratio S122
- Oxygen tension S252  
Oxygenation S185
- p21 S82  
p53 S82  
P450 S287  
P450 reductase S1, S19  
Pentose cycle S140  
Pentoxifylline S236  
Perfluorocarbon S226  
Perfusion S241  
Perfusion rate S252  
pH glycolysis S222  
Phenanthridine S28  
Photofrin S89  
Pimnidazole S28  
Potential tumour cell doubling time S279  
Proamine S99  
Pulse radiolysis S172
- Quinones S23
- Radiation S39, S61, S82, S114, S122, S181  
Radiation effects S105  
Radiation protective agents S89  
Radiation response S78  
Radiation sensitivity S19, S247  
Radicals S70  
Radioprotection S102  
Radiosensitisers S117, S271, S282  
Radiotherapy S271, S282  
Rate constants S70  
RB6145 S168  
RB90740 S70  
RE 90740 S57  
Red cell flux S247  
Relative biological effectiveness S122  
Reoxygenation S191  
Repopulation S279
- S-phase sensitisers S294  
SaF murine tumour S260  
Sarafotoxin S6c S161  
SCCVII mouse tumour S114  
Sensitisation S181  
Sensitiser enhancement ratio S294  
Single photon emission computed tomography S204  
Spheroids S78  
SR-2508 S267





- Sulphydryl depletion S117  
Superoxides S157  
Suppressor genes S136
- T.199 S93  
Taxol S82  
Tetraploidisation S136  
Therapeutic gain S39  
THNLA-1 S267  
Time-resolved fluorescence S256  
Tirapazamine S1, S39, S61, S70, S86
- TNF $\alpha$ , *see* Tumour necrosis factor  $\alpha$   
Topoisomerase inhibitors S43  
Total body irradiation S105  
Transcription factors S145  
Tumours, human S185  
Tumour blood flow S161  
Tumour control probability S185  
Tumour imaging S264  
Tumour microenvironment S133, S164
- Tumour necrosis factor  $\alpha$  S133  
Tumour oxygenation S133, S177, S217, S232, S256
- U937 cells S133
- V79 cells S109  
Vascular endothelial growth factor S126  
Vascular homeostasis S247
- Vascular resistance S161  
Vascular tone S177  
Vasoactive agents S232, S241  
Vinblastine S75, S82, S86
- Wound healing S151  
WR-2721 S89  
WR-3689 S89
- Xanthine oxidase S1  
Xylazine S222